K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Elinor Chelsom Vogt in
Google Scholar
PubMed
Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
Search for other papers by Francisco Gómez Real in
Google Scholar
PubMed
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Eystein Sverre Husebye in
Google Scholar
PubMed
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Sigridur Björnsdottir in
Google Scholar
PubMed
Department of Sleep, Landspitali University Hospital Reykjavík, Reykjavik, Iceland
Search for other papers by Bryndis Benediktsdottir in
Google Scholar
PubMed
Search for other papers by Randi Jacobsen Bertelsen in
Google Scholar
PubMed
Search for other papers by Pascal Demoly in
Google Scholar
PubMed
Search for other papers by Karl Anders Franklin in
Google Scholar
PubMed
Search for other papers by Leire Sainz de Aja Gallastegui in
Google Scholar
PubMed
Search for other papers by Francisco Javier Callejas González in
Google Scholar
PubMed
Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
Search for other papers by Joachim Heinrich in
Google Scholar
PubMed
Search for other papers by Mathias Holm in
Google Scholar
PubMed
Search for other papers by Nils Oscar Jogi in
Google Scholar
PubMed
Search for other papers by Benedicte Leynaert in
Google Scholar
PubMed
Search for other papers by Eva Lindberg in
Google Scholar
PubMed
Search for other papers by Andrei Malinovschi in
Google Scholar
PubMed
Albacete Faculty of Medicine, Castilla-La Mancha University, Albacete, Spain
Search for other papers by Jesús Martínez-Moratalla in
Google Scholar
PubMed
Search for other papers by Raúl Godoy Mayoral in
Google Scholar
PubMed
Search for other papers by Anna Oudin in
Google Scholar
PubMed
Search for other papers by Antonio Pereira-Vega in
Google Scholar
PubMed
Search for other papers by Chantal Raherison Semjen in
Google Scholar
PubMed
The National Research Center for the Working Environment, Copenhagen, Denmark
Search for other papers by Vivi Schlünssen in
Google Scholar
PubMed
Search for other papers by Kai Triebner in
Google Scholar
PubMed
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Marianne Øksnes in
Google Scholar
PubMed
AS . Changes in body composition and weight during the menopause transition . JCI Insight 2019 4 e124865 . ( https://doi.org/10.1172/jci.insight.124865 ) 46 Waaseth M Bakken K Lund E . Patterns of hormone therapy use in the Norwegian Women
Search for other papers by Panagiotis Anagnostis in
Google Scholar
PubMed
Search for other papers by Irene Lambrinoudaki in
Google Scholar
PubMed
Search for other papers by John C Stevenson in
Google Scholar
PubMed
Search for other papers by Dimitrios G Goulis in
Google Scholar
PubMed
effect of menopausal hormone therapy (MHT) on this risk is also discussed. Does transition to menopause predispose to higher CVD risk? Menopause, defined as the completion of 12 months since the final menstrual period (FMP) or at the time of
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
of treatment is to replace thyroid function but, in the latter condition, an additional aim is to keep the serum thyroid-stimulating hormone (TSH) at the lower limit of the normal range and possibly below (TSH suppressive therapy) to improve the
Division of Reproductive & Developmental Sciences, Oregon National Primate Research Center, Beaverton, Oregon, USA
Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon, USA
Department of Physiology & Pharmacology, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Henryk F Urbanski in
Google Scholar
PubMed
Search for other papers by Kevin Mueller in
Google Scholar
PubMed
Division of Reproductive & Developmental Sciences, Oregon National Primate Research Center, Beaverton, Oregon, USA
Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Cynthia L Bethea in
Google Scholar
PubMed
unclear if age-associated perturbations of activity-rest cycles and alterations in circadian hormone patterns are exacerbated after menopause by maintenance on a typical high-fat, high-sugar WSD and, more importantly, if these changes can be overcome by E
Search for other papers by Kristin Ottarsdottir in
Google Scholar
PubMed
Search for other papers by Margareta Hellgren in
Google Scholar
PubMed
Search for other papers by David Bock in
Google Scholar
PubMed
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Anna G Nilsson in
Google Scholar
PubMed
Search for other papers by Bledar Daka in
Google Scholar
PubMed
–2014. Of those, 1327 (participation rate 68%; M = 657) participants completed the study protocol at visit 2 accordingly. Eligible for the present study were those without insulin therapy or hormone replacement therapy. Only subjects that could provide full
Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France
Search for other papers by Emmanuelle Noirrit in
Google Scholar
PubMed
Search for other papers by Mélissa Buscato in
Google Scholar
PubMed
Search for other papers by Marion Dupuis in
Google Scholar
PubMed
CHU de Toulouse, Laboratoire d’Hématologie, Toulouse, France
Search for other papers by Bernard Payrastre in
Google Scholar
PubMed
Search for other papers by Coralie Fontaine in
Google Scholar
PubMed
Search for other papers by Jean-François Arnal in
Google Scholar
PubMed
Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France
Search for other papers by Marie-Cécile Valera in
Google Scholar
PubMed
and/or placebo-controlled studies, called the Selective estrogens, Menopause And Response to Therapy (SMART) trials ( 9 , 12 , 13 , 14 , 15 , 16 ). From these trials, CE + BZA were found to be associated with significant benefits such as a
Search for other papers by Enrique Pedernera in
Google Scholar
PubMed
Search for other papers by Flavia Morales-Vásquez in
Google Scholar
PubMed
Search for other papers by María J Gómora in
Google Scholar
PubMed
Search for other papers by Miguel A Almaraz in
Google Scholar
PubMed
Universidad La Salle, Posgrado de la Facultad de Ciencias Químicas, Ciudad de México, México
Search for other papers by Esteban Mena in
Google Scholar
PubMed
Search for other papers by Delia Pérez-Montiel in
Google Scholar
PubMed
Search for other papers by Elizabeth Rendon in
Google Scholar
PubMed
Search for other papers by Horacio López-Basave in
Google Scholar
PubMed
Search for other papers by Juan Maldonado-Cubas in
Google Scholar
PubMed
Search for other papers by Carmen Méndez in
Google Scholar
PubMed
in tumor cell proliferation after E2 treatment ( 28 ). Moreover, hormone replacement therapy in menopausal women is recognized as a risk factor for ovarian cancer ( 29 ); consequently, tumor progression associated with the presence of E2 might be
Search for other papers by Keina Nishio in
Google Scholar
PubMed
Search for other papers by Akiko Tanabe in
Google Scholar
PubMed
Search for other papers by Risa Maruoka in
Google Scholar
PubMed
Search for other papers by Kiyoko Nakamura in
Google Scholar
PubMed
Search for other papers by Masaaki Takai in
Google Scholar
PubMed
Search for other papers by Tatsuharu Sekijima in
Google Scholar
PubMed
Search for other papers by Satoshi Tunetoh in
Google Scholar
PubMed
Search for other papers by Yoshito Terai in
Google Scholar
PubMed
Search for other papers by Masahide Ohmichi in
Google Scholar
PubMed
) . Osteoporosis is common in women with breast cancer who receive chemotherapy, hormone therapy, or surgical castration, because these treatments induce bone loss (8) . Atkinson et al . (9) reported that prepubertal children with lymphoblastic leukemia who
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Brendan J Nolan in
Google Scholar
PubMed
Search for other papers by Aviva S Frydman in
Google Scholar
PubMed
Search for other papers by Shalem Y Leemaqz in
Google Scholar
PubMed
Search for other papers by Meg Carroll in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Ada S Cheung in
Google Scholar
PubMed
development in a prospective study ( 7 ). There are currently no data with micronised progesterone. Micronised progesterone is often prescribed for endometrial protection with oestradiol as menopausal hormone therapy for cisgender women with an intact uterus
Search for other papers by Hyun-Ah Kim in
Google Scholar
PubMed
Search for other papers by Jihye Choi in
Google Scholar
PubMed
Search for other papers by Chan Sub Park in
Google Scholar
PubMed
Search for other papers by Min-Ki Seong in
Google Scholar
PubMed
Search for other papers by Sung-Eun Hong in
Google Scholar
PubMed
Search for other papers by Jae-Sung Kim in
Google Scholar
PubMed
Search for other papers by In-Chul Park in
Google Scholar
PubMed
Search for other papers by Jin Kyung Lee in
Google Scholar
PubMed
Search for other papers by Woo Chul Noh in
Google Scholar
PubMed
Search for other papers by the ASTRRA trial investigators in
Google Scholar
PubMed
-induced amenorrhoea, side effects such as aggravated menopausal symptoms and bone health issues pose a limitation ( 8 , 9 ). Therefore, a reliable and feasible biomarker for predicting ovarian function recovery would help in deciding optimal endocrine therapy